Neuromodulation Devices Market Top Leading Players with Strategies and Forecast 2027
MRFR Projects a Steady Growth in Worldwide Sales
of Neuromodulation Devices Over the Next Nine Years
In 2017, sales of neuromodulation devices
remained on the upside and a similar trend is likely to follow in 2018.
Neuromodulation has gained significant traction over the past couple of years,
which has reflected favourably on the global market for neuromodulation
devices. These devices are also finding applications in minimally invasive
surgeries and several neuromodulation therapies. The recent study conducted by
Market Research Future (MRFR) claims that global neuromodulation devices sales
will remain steady over the next nine years.
Neuromodulation is increasingly being used in
healthcare to leverage the power of electrical impulses for therapeutic
benefits. While several new areas of use have emerged in recent years, deep
brain stimulation (DBS) remains the primary healthcare application of
neuromodulation. DBS is a therapeutic technique focused towards resolving
chronic and intractable pain. Such pains are quite common among the elderly
population; the latest data resealed by United Nations suggest that the number
of older persons — those aged 60 years or above — is expected to more than
double by 2050.
The rising number and proportion of elderly
people is almost all the countries in the world is creating diverse healthcare
requirements. This, in turn, is expected to support the growth of the global
market for neuromodulation devices in the forthcoming years. Other factors that
are expected to have a positive impact on the market include increasing
incidence of neurological disorder, advances in technology, device
miniaturization and arrival of new neuromodulation devices. Moreover, faster
approval rate of new neuromodulation technologies is encouraging players to
concentrate on their R&D pipelines. However, new entrants will have to
overcome formidable challenges in order to compete with established players who
collectively account for a controlling stake of the market. Mergers and
acquisitions are expected to remain a key trend in the industry as big players
focus on expansion and local vendors try to leverage the know-hows of industry
leaders. Offering new and novel solutions will be key to achieving a
competitive edge in the market.
Get Sample Report: https://www.marketresearchfuture.com/sample_request/1337
Global Neuromodulation
Devices Market: Competitive Landscape
Medtronic (Ireland), St.
Jude Medical, Inc. (U.S.), Nevro Corp (U.S.), NeuroSigma, Inc.(U.S.),
Neuronetics, Inc. (U.S.), BioControl Medical (Israel), DynaMD, Accellent (U.S),
Synapse Biomedical Inc. (U.S.), Boston Scientific Corporation (U.S.), NeuroPace,
Inc. (U.S.), and Soterix Medical Inc. (U.S) are some of key market participants
profiled in MRFR’s report.
Global Neuromodulation Devices Market: Segmental
Analysis
Based on type, the
market has been segmented into time domain and spectral domain.
Based on techniques, the market has been segmented into doppler neuromodulation
devices, polarization-sensitive neuromodulation devices, and adaptive optics
neuromodulation devices.
Based on applications the market has been segmented into eyes imaging and diabetic
retinopathy.
Regional Outlook
Among regions, North America currently accounts
for a noteworthy share of the market and expected to present lucrative growth
opportunities for players in 2018 and beyond. Presence of leading healthcare
technology companies in the region is major advantage for the market in North
America. In addition, high healthcare expenditure and awareness about
availability of advanced medical treatment modules is propelling the growth of
the market in the
region. North America is followed by Europe and
Asia Pacific (APAC) respectively.
Industry Trends and News
·
Medtronic plc recently announced that the company
has been shown a green signal by the U.S. FDA in its pursue of introducing a
new spine surgery indication “Infuse™ Bone Graft”. After the FDA clearance, the
company can now use the technology during additional spine implants procedures
such as anterior lumbar interbody fusion (ALIF) and oblique lateral interbody
fusion (OLIF 25(TM) and OLIF 51(TM)).
·
Synapse Biomedical, the manufacturer of the NeuRx
Diaphragm Pacing System® and a specialist in neurostimulation recently
announced the it receive the CE Mark approval for its new temporary diaphragm
stimulator “TransAeris™ System”.
Browse
Full Report: https://www.marketresearchfuture.com/reports/neuromodulation-devices-market-1337
Browse
Related Report: Urinary
Tract Infection Market
Central
Nervous System Biomarkers Market
Host
Cell Protein Testing Market
Dry
Age-Related Macular Degeneration Market
About
US:
Market
Research Future (MRFR) enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact
us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street,5The Floor, New York,
New
York 10013
Comments
Post a Comment